Novartis' China plans grew from science roundtables

PharmAsia News sat down with Paul Herrling, head of corporate research at Novartis, and En Li, VP and head of research for Novartis Institutes for BioMedical Research Shanghai, to discuss the massive R&D efforts the company now has underway in China.

Novartis began its involvement in China 10 years ago with discussions with Chinese scientists about traditional Chinese therapeutics and how that fit in with Novartis' effort to develop new compounds using natural ingredients. Now Novartis is budgeting $96 million for a new R&D center in China and plans to make the Chinese market one of its top 10 globally.

- read the story from In Vivo

Related Articles:
R&D spending going gangbusters in China
Novartis maps $100M R&D complex in China

Suggested Articles

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.

The delay will enable Anixa to perform additional genetic engineering intended to boost the efficacy of the treatment in ovarian cancer.